Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

bal, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

* Unless otherwise noted, all event rates and p-values are based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

** Stent thrombosis rates are based on binary event rates, and p-values are based on Fisher's Exact Test; p-values are for descriptive purposes only.

*** Subgroup event rates are based on binary event rates.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... ... September 01, 2015 , ... Mercy Health (formerly Catholic Health ... 10th of its monthly Mercy Health: Helping You Be Well videos to prostate cancer ... men. , In a concise video on Mercy Health’s YouTube channel, Mercy Health ...
(Date:9/1/2015)... Beach, FL (PRWEB) , ... September 01, 2015 ... ... pharmacy discount cards, launched its consumer-friendly, informational video this week to coincide with ... http://www.USAMedicalCard.com/video . , According to the CDC, elementary school children are ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and pick-up artists about their experiences of female beauty, women’s emotions, fertility, female ... penis issues, as well as their relationships with other men, documenting how the ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In America”, hosted ... at the topic of arthritis. There are over 100 different types of arthritis. One ... and statistics in an effort to shed light on this important topic. , Anyone ...
Breaking Medicine News(10 mins):Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... mark, but numbers aren,t as high as some might suspect, ... risk of relapse can linger for some breast cancer survivors ... therapy, a new study found. , But, as gloomy as ... risk may not be as dire as many women fear. ...
... Urged to End Role as It Did with ... For the second time in,recent weeks, international ... to withdraw its sponsorship and promotion of a ... company,s activities appear,to violate national law., Last ...
... 12 Smart Balance, Inc.,(Nasdaq: SMBL ) announced ... Balance, Inc., will make a presentation at the Canaccord,Adams ... EDT on Thursday,August 14, 2008., Smart Balance,s presentation ... will be able to ask questions, but,listeners will be ...
... settle question about best treatment for the disease , , ... from a European study that has followed men with ... debate about the advantages of aggressive treatment versus "watchful ... men who underwent surgery to remove the prostate disappeared ...
... Aug. 12 Holland America Line has surpassed the,million-dollar ... the,Cure(R) via its On Deck for the Cure program, ... The line will celebrate the milestone,this week with special ... at its corporate headquarters in Seattle., Since the ...
... Minn. -- Online Internet shopping today offers many benefits. ... your own home and purchase most anything by clicking ... prescription drugs via the Internet, bypassing a traditional office ... issue of Mayo Clinic Proceedings , researchers from ...
Cached Medicine News:Health News:Risk of Breast Cancer Relapse Can Linger 2Health News:Risk of Breast Cancer Relapse Can Linger 3Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 2Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 3Health News:Smart Balance to Webcast Presentation at Canaccord Adams Global Growth Conference 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 2Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 4Health News:Researchers examine safety of Internet prescriber service providing erectile dysfunction medications 2
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Lifestyle Gp is a ... multi-aspheric back surface. Through a ... surface curves, the LifeStyle Gp ... of add. Plus, its multi-aspheric ...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: